Efficacy, Safety, and Potential Biomarkers of Thalidomide plus Metronomic Chemotherapy for Advanced Hepatocellular Carcinoma

Efficacy, Safety, and Potential Biomarkers of Thalidomide plus Metronomic Chemotherapy for Advanced Hepatocellular Carcinoma is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1159/000336126
P698PubMed publication ID22310088

P50authorAnn-Lii ChengQ38639483
Yu-yun ShaoQ43072370
Chih-Hung HsuQ57032765
P2093author name stringZhong-Zhe Lin
Chiun Hsu
Yen-Shen Lu
Kuan-Der Lee
Chien-Chung Huang
Chi-Huang Hsiao
Yin-Chun Shen
P2860cites workContinuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicityQ24561642
Sorafenib in advanced hepatocellular carcinomaQ27861075
A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lungQ28258014
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trialQ29547903
Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma.Q33382749
Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II studyQ33384665
Interleukin-6 trans-signalling differentially regulates proliferation, migration, adhesion and maspin expression in human prostate cancer cellsQ33690450
Impact of metronomic UFT/cyclophosphamide chemotherapy and antiangiogenic drug assessed in a new preclinical model of locally advanced orthotopic hepatocellular carcinomaQ33728605
Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinomaQ33747394
Development of a Resistance-like Phenotype to Sorafenib by Human Hepatocellular Carcinoma Cells Is Reversible and Can Be Delayed by Metronomic UFT ChemotherapyQ34300621
The interleukin-8 pathway in cancer.Q34871322
Interleukin-6 and chronic inflammationQ35578869
The anti-angiogenic basis of metronomic chemotherapyQ35788112
Salvage therapy for hepatocellular carcinoma with thalidomideQ36474106
Advanced hepatocellular carcinoma: which staging systems best predict prognosis?Q36836103
Interleukin-8 is associated with proliferation, migration, angiogenesis and chemosensitivity in vitro and in vivo in colon cancer cell line models.Q39677535
Interleukin-8 signaling promotes androgen-independent proliferation of prostate cancer cells via induction of androgen receptor expression and activationQ39980991
Effects of thalidomide and related metabolites in a mouse corneal model of neovascularizationQ42547622
Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinomaQ43008115
Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinomaQ43086833
Low-dose thalidomide treatment for advanced hepatocellular carcinomaQ44681352
Phase II study of thalidomide in patients with unresectable hepatocellular carcinomaQ44865180
Thalidomide in the treatment of patients with hepatocellular carcinoma: a phase II trialQ45231163
Optimal two-stage designs for phase II clinical trialsQ46412217
Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factorQ47912802
Interleukin 8 in human hepatocellular carcinoma correlates with cancer cell invasion of vessels but not with tumor angiogenesis.Q54646245
P433issue1
P921main subjectbiomarkerQ864574
chemotherapyQ974135
hepatocellular carcinomaQ1148337
cancer researchQ3421914
P304page(s)59-66
P577publication date2012-01-01
P1433published inOncologyQ2016300
P1476titleEfficacy, Safety, and Potential Biomarkers of Thalidomide plus Metronomic Chemotherapy for Advanced Hepatocellular Carcinoma
P478volume82

Reverse relations

cites work (P2860)
Q33872982A comparative study of sorafenib and metronomic chemotherapy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma with poor liver function
Q38249998A systematic literature analysis of correlative studies in low-dose metronomic chemotherapy trials.
Q27693179Chemotherapeutic agents for the treatment of hepatocellular carcinoma: efficacy and mode of action
Q38788234Current achievements and future perspectives of metronomic chemotherapy
Q36182824Efficacy, safety, and biomarkers of single-agent bevacizumab therapy in patients with advanced hepatocellular carcinoma
Q92764511Evaluation of oral tegafur-uracil as metronomic therapy following concurrent chemoradiotherapy in patients with non-distant metastatic TNM stage IV nasopharyngeal carcinoma
Q47692343High plasma interleukin-6 levels associated with poor prognosis of patients with advanced hepatocellular carcinoma
Q48226736Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy.
Q64071354Metronomic Chemotherapy: A Systematic Review of the Literature and Clinical Experience
Q38087885Metronomic chemotherapy for cancer treatment: a decade of clinical studies
Q37236004Metronomic chemotherapy: possible clinical application in advanced hepatocellular carcinoma
Q38910274Modified CLIP with objective liver reserve assessment retains prognosis prediction for patients with advanced hepatocellular carcinoma
Q26799458Optimal combination of antiangiogenic therapy for hepatocellular carcinoma
Q36318341Oral tegafur-uracil as metronomic therapy following intravenous FOLFOX for stage III colon cancer
Q57138867Potentiating cancer vaccine efficacy in liver cancer
Q37088265Predictive biomarkers of antiangiogenic therapy for advanced hepatocellular carcinoma: where are we?
Q36385705Prognosis of advanced hepatocellular carcinoma patients enrolled in clinical trials can be classified by current staging systems.
Q64063956Targeting myeloid-derived suppressor cells in the treatment of hepatocellular carcinoma: current state and future perspectives

Search more.